The recent outbreak of COVID-19 has provided new insight into the importance of communicating science to the public and policymakers, health equity issues, and the global aspects of a pandemic. In this interview, Dr John Sharfstein (Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA) discusses the importance of effective science communication and its challenges during the COVID-19 pandemic.
‘Communicating Science to the Public and to Policy Makers during a Pandemic’ was presented at the annual International Conference on Emerging Infectious Diseases (ICEID), August 7–10, 2022.
- What are the key concepts of effective science communication? (00:12)
- What have been the major challenges in communicating science to the public and policy makers during the COVID-19 pandemic? (00:40)
- What are the consequences of failures of communication? (01:30)
- Could you provide some examples of successes and failure of communication during the COVID-19 pandemic? (02:04)
- In terms of communication, what lessons have we learned from the COVID-19 pandemic? (03:10)
Disclosures: John Sharfstein has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Marianna Mignani.
Filmed as a highlight of ICEID 2022.
Share this Video
Related Videos In COVID-19
Molnupiravir, an oral antiviral against SARS-CoV-2: Chris Butler, ECCMID 2023
Molnupiravir, an oral antiviral against SARS-CoV-2 was first granted emergency use authorisation in 2021 to reduce the risk of hospitalisation and death in mild to moderate COVID-19 with increased risk of developing severe disease. We were delighted to speak with Prof. Chris Butler (University of Oxford, Oxford, UK) to discuss the mechanism of action of […]
PANORAMIC trial – Molnupiravir efficacy in adults with COVID-19 at increased risk of adverse outcomes: Chris Butler, ECCMID 2023
PANORAMIC (ISRCTN30448031) was a multicentre, open-label, randomized controlled trial investigating novel treatments for COVID-19 in the UK. We were delighted to speak with Prof. Chris Butler (University of Oxford, Oxford, UK) to discuss the PANORAMIC study results, and how these insights will optimise the use of molnupiravir in clinical practice. Catch up: Interview with Prof. […]
COVID-19 vaccine development, updates and advances: Christoph Spinner, ECCMID 2023
The COVID-19 pandemic brought about the accelerated development of vaccinations to protect against variants of SARS-CoV-2, recently new targets of broad protection against potential future variants have been outlined and numerous vaccine candidates are in pre-clinical and clinical development. It was a pleasure to speak with Editorial Board member Dr. Christoph Spinner (Technical University of […]